Elutia (ELUT) Competitors

$1.08 -0.02 (-1.82%)

As of 03:34 PM Eastern

ELUT vs. PRQR, IMUX, ADAG, ENLV, and HRTX

Should you buy Elutia stock or one of its competitors? MarketBeat compares Elutia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Elutia include ProQR Therapeutics (PRQR), Immunic (IMUX), Adagene (ADAG), Enlivex Therapeutics (ENLV), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry.

How does Elutia compare to ProQR Therapeutics?

Elutia (NASDAQ:ELUT) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Elutia currently has a consensus price target of $6.00, suggesting a potential upside of 455.56%. ProQR Therapeutics has a consensus price target of $7.25, suggesting a potential upside of 401.73%. Given Elutia's higher probable upside, equities research analysts clearly believe Elutia is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Elutia had 5 more articles in the media than ProQR Therapeutics. MarketBeat recorded 9 mentions for Elutia and 4 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.30 beat Elutia's score of -0.24 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elutia has a net margin of 312.09% compared to ProQR Therapeutics' net margin of -331.33%. Elutia's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-58.27%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Elutia has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.76	$53.38M	$0.86	1.26
ProQR Therapeutics	$17.99M	8.46	-$47.73M	-$0.50	N/A

Elutia has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

74.0% of Elutia shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 27.6% of Elutia shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Elutia beats ProQR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Elutia compare to Immunic?

Elutia (NASDAQ:ELUT) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Immunic had 12 more articles in the media than Elutia. MarketBeat recorded 21 mentions for Immunic and 9 mentions for Elutia. Immunic's average media sentiment score of -0.12 beat Elutia's score of -0.24 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunic	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elutia has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.76	$53.38M	$0.86	1.26
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

74.0% of Elutia shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 27.6% of Elutia shares are held by insiders. Comparatively, 14.0% of Immunic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Elutia has a net margin of 312.09% compared to Immunic's net margin of 0.00%. Elutia's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-58.27%
Immunic	N/A	-220.75%	-132.04%

Elutia has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Immunic has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Elutia currently has a consensus target price of $6.00, suggesting a potential upside of 455.56%. Immunic has a consensus target price of $50.86, suggesting a potential upside of 337.29%. Given Elutia's higher probable upside, equities research analysts clearly believe Elutia is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immunic	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Elutia beats Immunic on 10 of the 16 factors compared between the two stocks.

How does Elutia compare to Adagene?

Adagene (NASDAQ:ADAG) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Elutia has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	21.01	-$17.61M	N/A	N/A
Elutia	$12.29M	3.76	$53.38M	$0.86	1.26

In the previous week, Elutia had 9 more articles in the media than Adagene. MarketBeat recorded 9 mentions for Elutia and 0 mentions for Adagene. Adagene's average media sentiment score of 0.00 beat Elutia's score of -0.24 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Neutral
Elutia	Neutral

Adagene presently has a consensus price target of $8.00, suggesting a potential upside of 135.29%. Elutia has a consensus price target of $6.00, suggesting a potential upside of 455.56%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elutia has a net margin of 312.09% compared to Adagene's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Elutia	312.09%	N/A	-58.27%

Adagene has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Elutia has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

9.5% of Adagene shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Elutia beats Adagene on 8 of the 14 factors compared between the two stocks.

How does Elutia compare to Enlivex Therapeutics?

Elutia (NASDAQ:ELUT) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

74.0% of Elutia shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 27.6% of Elutia shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Elutia had 6 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 9 mentions for Elutia and 3 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.25 beat Elutia's score of -0.24 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elutia currently has a consensus target price of $6.00, suggesting a potential upside of 455.56%. Enlivex Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 2,237.11%. Given Enlivex Therapeutics' higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Elutia has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Elutia has a net margin of 312.09% compared to Enlivex Therapeutics' net margin of 0.00%. Enlivex Therapeutics' return on equity of 248.08% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-58.27%
Enlivex Therapeutics	N/A	248.08%	206.39%

Enlivex Therapeutics has lower revenue, but higher earnings than Elutia. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.76	$53.38M	$0.86	1.26
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

Summary

Elutia beats Enlivex Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Elutia compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Elutia has a net margin of 312.09% compared to Heron Therapeutics' net margin of -20.53%. Elutia's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Elutia	312.09%	N/A	-58.27%

Heron Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Elutia has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Heron Therapeutics currently has a consensus price target of $4.50, indicating a potential upside of 420.83%. Elutia has a consensus price target of $6.00, indicating a potential upside of 455.56%. Given Elutia's stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elutia has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$150.71M	1.09	-$20.19M	-$0.18	N/A
Elutia	$12.29M	3.76	$53.38M	$0.86	1.26

In the previous week, Elutia had 6 more articles in the media than Heron Therapeutics. MarketBeat recorded 9 mentions for Elutia and 3 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.01 beat Elutia's score of -0.24 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 5.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 27.6% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Elutia beats Heron Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Elutia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELUT vs. The Competition

Export

Metric	Elutia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$46.20M	$3.26B	$6.27B	$12.13B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	1.26	18.70	20.61	25.11
Price / Sales	3.76	281.88	578.26	91.48
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	1.66	6.59	9.72	6.63
Net Income	$53.38M	$24.30M	$3.55B	$335.73M
7 Day Performance	2.86%	-3.36%	-1.89%	-1.80%
1 Month Performance	-6.09%	-7.67%	-3.77%	-1.69%
1 Year Performance	-40.33%	52.30%	29.58%	27.59%

Elutia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELUT Elutia	2.8927 of 5 stars	$1.08 -1.8%	$6.00 +455.6%	-36.0%	$46.20M	$12.29M	1.26	180	News Coverage Earnings Report
PRQR ProQR Therapeutics	3.4112 of 5 stars	$1.70 +6.3%	$7.25 +326.5%	-6.8%	$179.11M	$17.99M	N/A	180	Earnings Report Analyst Downgrade
IMUX Immunic	3.8018 of 5 stars	$12.95 +8.8%	$52.43 +304.9%	+21.3%	$176.38M	N/A	N/A	70	Trending News Earnings Report Upcoming Earnings Analyst Revision
ADAG Adagene	2.7804 of 5 stars	$3.70 +1.1%	$8.00 +116.2%	+91.5%	$175.34M	$7.67M	N/A	260	Positive News Gap Down
ENLV Enlivex Therapeutics	2.3805 of 5 stars	$0.73 -2.3%	$16.50 +2,152.9%	-30.3%	$173.86M	N/A	N/A	70	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELUT) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elutia (ELUT) Competitors

ELUT vs. PRQR, IMUX, ADAG, ENLV, and HRTX

How does Elutia compare to ProQR Therapeutics?

Summary

How does Elutia compare to Immunic?

Summary

How does Elutia compare to Adagene?

Summary

How does Elutia compare to Enlivex Therapeutics?

Summary

How does Elutia compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elutia (ELUT) Competitors

ELUT vs. PRQR, IMUX, ADAG, ENLV, and HRTX

How does Elutia compare to ProQR Therapeutics?

Do analysts recommend ELUT or PRQR?

Does the media prefer ELUT or PRQR?

Is ELUT or PRQR more profitable?

Which has preferable earnings & valuation, ELUT or PRQR?

Which has more volatility & risk, ELUT or PRQR?

Do insiders and institutionals hold more shares of ELUT or PRQR?

Summary

How does Elutia compare to Immunic?

Does the media refer more to ELUT or IMUX?

Which has preferable valuation and earnings, ELUT or IMUX?

Do insiders & institutionals hold more shares of ELUT or IMUX?

Is ELUT or IMUX more profitable?

Which has more risk & volatility, ELUT or IMUX?

Do analysts rate ELUT or IMUX?

Summary

How does Elutia compare to Adagene?

Which has stronger valuation & earnings, ADAG or ELUT?

Does the media refer more to ADAG or ELUT?

Do analysts prefer ADAG or ELUT?

Is ADAG or ELUT more profitable?

Which has more risk & volatility, ADAG or ELUT?

Do insiders and institutionals have more ownership in ADAG or ELUT?

Summary

How does Elutia compare to Enlivex Therapeutics?

Do institutionals & insiders have more ownership in ELUT or ENLV?

Does the media refer more to ELUT or ENLV?

Do analysts prefer ELUT or ENLV?

Which has more volatility & risk, ELUT or ENLV?

Is ELUT or ENLV more profitable?

Which has better valuation and earnings, ELUT or ENLV?

Summary

How does Elutia compare to Heron Therapeutics?

Is HRTX or ELUT more profitable?

Which has more volatility and risk, HRTX or ELUT?

Do analysts prefer HRTX or ELUT?

Which has stronger valuation and earnings, HRTX or ELUT?

Does the media favor HRTX or ELUT?

Do institutionals and insiders have more ownership in HRTX or ELUT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools